Skip to main content
Top
Published in: Clinical and Translational Oncology 11/2017

01-11-2017 | Research Article

A logistic regression model predicting high axillary tumour burden in early breast cancer patients

Authors: I. Barco, M. García Font, A. García-Fernández, N. Giménez, M. Fraile, J. M. Lain, E. Vallejo, S. González, L. Canales, J. Deu, M. C. Vidal, M. Rodríguez-Carballeira, A. Pessarrodona, C. Chabrera

Published in: Clinical and Translational Oncology | Issue 11/2017

Login to get access

Abstract

Purpose

As elective axillary dissection is loosing ground for early breast cancer (BC) patients both in terms of prognostic and therapeutic power, there is a growing interest in predicting patients with (nodal) high tumour burden (HTB), especially after a positive sentinel node biopsy (SNB) because they would really benefit from further axillary intervention either by complete lymph-node dissection or axillary radiation therapy.

Methods/patients

Based on an analysis of 1254 BC patients in whom complete axillary clearance was performed, we devised a logistic regression (LR) model to predict those with HTB, as defined by the presence of three or more involved nodes with macrometastasis. This was accomplished through prior selection of every variable associated with HTB at univariate analysis.

Results

Only those variables shown as significant at the multivariate analysis were finally considered, namely tumour size, lymphovascular invasion and histological grade. A probability table was then built to calculate the chances of HTB from a cross-correlation of those three variables. As a suggestion, if we were to follow the rationale previously used in the micrometastasis trials, a threshold of about 10% risk of HTB could be considered under which no further axillary treatment is warranted.

Conclusions

Our LR model with its probability table can be used to define a subgroup of early BC patients suitable for axillary conservative procedures, either sparing completion lymph-node dissection or even SNB altogether.
Literature
1.
go back to reference Fraile M, Rull M, Julián FJ, Fusté F, Barnadas A, Llatjós M, et al. Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: an approach to its validity. Ann Oncol. 2000;11:701–5.CrossRefPubMed Fraile M, Rull M, Julián FJ, Fusté F, Barnadas A, Llatjós M, et al. Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: an approach to its validity. Ann Oncol. 2000;11:701–5.CrossRefPubMed
2.
go back to reference Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.CrossRefPubMedPubMedCentral Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.CrossRefPubMedPubMedCentral
3.
go back to reference Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10.CrossRefPubMedPubMedCentral Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15:1303–10.CrossRefPubMedPubMedCentral
4.
go back to reference Bundred NJ, Barnes NL, Rutgers E, Donker M. Is axillary lymph node clearance required in node-positive breast cancer? Nat Rev Clin Oncol. 2015;12:55–61.CrossRefPubMed Bundred NJ, Barnes NL, Rutgers E, Donker M. Is axillary lymph node clearance required in node-positive breast cancer? Nat Rev Clin Oncol. 2015;12:55–61.CrossRefPubMed
5.
go back to reference Gatzemeier W, Mann GB. Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND)—ACOSOG Z0011 results and beyond. Breast. 2013;22:211–6.CrossRefPubMed Gatzemeier W, Mann GB. Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND)—ACOSOG Z0011 results and beyond. Breast. 2013;22:211–6.CrossRefPubMed
6.
go back to reference van la Parra RF, Peer PG, de Roos WK, Ernst MF, de Wilt JH, Bosscha K. A simple risk score to predict the presence of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node. World J Surg. 2014;38:1070–6.CrossRef van la Parra RF, Peer PG, de Roos WK, Ernst MF, de Wilt JH, Bosscha K. A simple risk score to predict the presence of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node. World J Surg. 2014;38:1070–6.CrossRef
7.
go back to reference Toshikawa C, Koyama Y, Nagahashi M, Tatsuda K, Moro K, Tsuchida J, et al. Predictive factors for non-sentinel lymph node metastasis in the case of positive sentinel lymph node metastasis in two or fewer nodes in breast cancer. J Clin Med Res. 2015;7:620–6.CrossRefPubMedPubMedCentral Toshikawa C, Koyama Y, Nagahashi M, Tatsuda K, Moro K, Tsuchida J, et al. Predictive factors for non-sentinel lymph node metastasis in the case of positive sentinel lymph node metastasis in two or fewer nodes in breast cancer. J Clin Med Res. 2015;7:620–6.CrossRefPubMedPubMedCentral
8.
go back to reference Stitzenberg KB, Meyer AA, Stern SL, Cance WG, Calvo BF, Klauber-DeMore N, et al. Extracapsular extension of the sentinel lymph node metastasis: a predictor of nonsentinel node tumor burden. Ann Surg. 2003;237:607–13.PubMedPubMedCentral Stitzenberg KB, Meyer AA, Stern SL, Cance WG, Calvo BF, Klauber-DeMore N, et al. Extracapsular extension of the sentinel lymph node metastasis: a predictor of nonsentinel node tumor burden. Ann Surg. 2003;237:607–13.PubMedPubMedCentral
9.
go back to reference Barco I, Chabrera C, García-Fernández A, Fraile M, Vidal M, González S, et al. Role of axillary ultrasound, magnetic resonance imaging, and ultrasound-guided fine-needle aspiration biopsy in the preoperative triage of breast cancer patients. Eur J Radiol. 2016;85:1786–93.CrossRefPubMed Barco I, Chabrera C, García-Fernández A, Fraile M, Vidal M, González S, et al. Role of axillary ultrasound, magnetic resonance imaging, and ultrasound-guided fine-needle aspiration biopsy in the preoperative triage of breast cancer patients. Eur J Radiol. 2016;85:1786–93.CrossRefPubMed
10.
go back to reference Futamura M, Asano T, Kobayashi K, Morimitsu K, Nawa M, Kanematsu M, et al. Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT. World J Surg Oncol. 2015;13:49.CrossRefPubMedPubMedCentral Futamura M, Asano T, Kobayashi K, Morimitsu K, Nawa M, Kanematsu M, et al. Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT. World J Surg Oncol. 2015;13:49.CrossRefPubMedPubMedCentral
11.
go back to reference Coutant C, Olivier C, Lambaudie E, Fondrinier E, Marchal F, Guillemin F, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27:2800–8.CrossRefPubMed Coutant C, Olivier C, Lambaudie E, Fondrinier E, Marchal F, Guillemin F, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27:2800–8.CrossRefPubMed
12.
go back to reference Barco I, García-Fernández A, Chabrera C, Fraile M, Vallejo E, Lain JM, et al. The appropriate axillary procedure after a positive sentinel node in breast cancer patients: the “Hôpital Tenon” score revisited. A two-institution study. Clin Transl Oncol. 2016;18:1098–105.CrossRefPubMed Barco I, García-Fernández A, Chabrera C, Fraile M, Vallejo E, Lain JM, et al. The appropriate axillary procedure after a positive sentinel node in breast cancer patients: the “Hôpital Tenon” score revisited. A two-institution study. Clin Transl Oncol. 2016;18:1098–105.CrossRefPubMed
13.
go back to reference Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.CrossRefPubMedPubMedCentral Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.CrossRefPubMedPubMedCentral
14.
go back to reference Zhu L, Jin L, Li S, Chen K, Jia W, Shan Q, et al. Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis. Breast Cancer Res Treat. 2013;137:783–95.CrossRefPubMed Zhu L, Jin L, Li S, Chen K, Jia W, Shan Q, et al. Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis. Breast Cancer Res Treat. 2013;137:783–95.CrossRefPubMed
15.
go back to reference Xie F, Yang H, Wang S, Zhou B, Tong F, Yang D, Zhang J. A logistic regression model for predicting axillary lymph node metastases in early breast carcinoma patients. Sensors (Basel). 2012;12:9936–50.CrossRef Xie F, Yang H, Wang S, Zhou B, Tong F, Yang D, Zhang J. A logistic regression model for predicting axillary lymph node metastases in early breast carcinoma patients. Sensors (Basel). 2012;12:9936–50.CrossRef
16.
go back to reference Li CZ, Zhang P, Li RW, Wu CT, Zhang XP, Zhu HC. Axillary lymph node dissection versus sentinel lymph node biopsy alone for early breast cancer with sentinel node metastasis: a meta-analysis. Eur J Surg Oncol. 2015;41:958–66.CrossRefPubMed Li CZ, Zhang P, Li RW, Wu CT, Zhang XP, Zhu HC. Axillary lymph node dissection versus sentinel lymph node biopsy alone for early breast cancer with sentinel node metastasis: a meta-analysis. Eur J Surg Oncol. 2015;41:958–66.CrossRefPubMed
17.
go back to reference García-Fernández A, Chabrera C, García-Font M, Giménez N, Barco I, Lain JM, et al. Breast cancer patients undergoing sentinel node biopsy: additional axillary tumor burden as a function of the total number of excised sentinel nodes—a multicenter study. Clin Breast Cancer. 2015;15:490–7.CrossRefPubMed García-Fernández A, Chabrera C, García-Font M, Giménez N, Barco I, Lain JM, et al. Breast cancer patients undergoing sentinel node biopsy: additional axillary tumor burden as a function of the total number of excised sentinel nodes—a multicenter study. Clin Breast Cancer. 2015;15:490–7.CrossRefPubMed
18.
go back to reference García Fernández A, Fraile M, Giménez N, Reñe A, Torras M, Canales L, et al. Use of axillary ultrasound, ultrasound-fine needle aspiration biopsy and magnetic resonance imaging in the preoperative triage of breast cancer patients considered for sentinel node biopsy. Ultrasound Med Biol. 2011;37:16–22.CrossRefPubMed García Fernández A, Fraile M, Giménez N, Reñe A, Torras M, Canales L, et al. Use of axillary ultrasound, ultrasound-fine needle aspiration biopsy and magnetic resonance imaging in the preoperative triage of breast cancer patients considered for sentinel node biopsy. Ultrasound Med Biol. 2011;37:16–22.CrossRefPubMed
19.
go back to reference Verheuvel NC, Ooms HW, Tjan-Heijnen VC, Roumen RM, Voogd AC. Predictors for extensive nodal involvement in breast cancer patients with axillary lymph node metastases. Breast. 2016;27:175–81.CrossRefPubMed Verheuvel NC, Ooms HW, Tjan-Heijnen VC, Roumen RM, Voogd AC. Predictors for extensive nodal involvement in breast cancer patients with axillary lymph node metastases. Breast. 2016;27:175–81.CrossRefPubMed
20.
go back to reference Tinterri C, Canavese G, Bruzzi P, Dozin B. SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes. Breast. 2016;30:197–200.CrossRefPubMed Tinterri C, Canavese G, Bruzzi P, Dozin B. SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes. Breast. 2016;30:197–200.CrossRefPubMed
21.
go back to reference Solá M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013;20:120–7.CrossRefPubMed Solá M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregas R, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013;20:120–7.CrossRefPubMed
Metadata
Title
A logistic regression model predicting high axillary tumour burden in early breast cancer patients
Authors
I. Barco
M. García Font
A. García-Fernández
N. Giménez
M. Fraile
J. M. Lain
E. Vallejo
S. González
L. Canales
J. Deu
M. C. Vidal
M. Rodríguez-Carballeira
A. Pessarrodona
C. Chabrera
Publication date
01-11-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 11/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1737-8

Other articles of this Issue 11/2017

Clinical and Translational Oncology 11/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine